[{"id":"4ae271df-843f-4292-9867-8d901b35d784","acronym":"PIPOZA","url":"https://clinicaltrials.gov/study/NCT06812715","created_at":"2025-02-25T16:42:55.747Z","updated_at":"2025-02-25T16:42:55.747Z","phase":"Phase 2","brief_title":"Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated with Pirtobrutinib After Previous Treatment with Zanubrutinib","source_id_and_acronym":"NCT06812715 - PIPOZA","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" BTK","pipe":"","alterations":" ","tags":["BTK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib) • Jaypirca (pirtobrutinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/01/2025","start_date":" 05/01/2025","primary_txt":" Primary completion: 05/01/2029","primary_completion_date":" 05/01/2029","study_txt":" Completion: 05/01/2031","study_completion_date":" 05/01/2031","last_update_posted":"2025-02-06"},{"id":"37db9b88-cfea-407b-b290-ec67bb7844d2","acronym":"EPCORE NHL-5","url":"https://clinicaltrials.gov/study/NCT05283720","created_at":"2022-03-17T12:53:27.504Z","updated_at":"2025-02-25T16:54:10.677Z","phase":"Phase 2","brief_title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05283720 - EPCORE NHL-5","lead_sponsor":"Genmab","biomarkers":" BCL2 • CD20 • CCND1 • BCL6","pipe":" | ","alterations":" Chr t(11;14)","tags":["BCL2 • CD20 • CCND1 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • prednisone • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp) • Polivy (polatuzumab vedotin-piiq) • golcadomide (CC-99282)"],"overall_status":"Recruiting","enrollment":" Enrollment 622","initiation":"Initiation: 06/14/2022","start_date":" 06/14/2022","primary_txt":" Primary completion: 11/01/2032","primary_completion_date":" 11/01/2032","study_txt":" Completion: 11/01/2032","study_completion_date":" 11/01/2032","last_update_posted":"2025-02-04"},{"id":"08b82509-fbbd-4719-b2fe-d7db759f217f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05529069","created_at":"2022-09-06T17:03:18.330Z","updated_at":"2024-07-02T16:35:07.866Z","phase":"Phase 2","brief_title":"Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients","source_id_and_acronym":"NCT05529069","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • MYC • BCL2 • CDKN2A • CCND1 • NOTCH2 • NSD2","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • Chr t(11;14) • CDKN2A mutation • CCND1 overexpression • Chr t(11;14)(q13;q32) • MYC positive • BCL2 amplification","tags":["TP53 • MYC • BCL2 • CDKN2A • CCND1 • NOTCH2 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • Chr t(11;14) • CDKN2A mutation • CCND1 overexpression • Chr t(11;14)(q13;q32) • MYC positive • BCL2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Jaypirca (pirtobrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/25/2023","start_date":" 01/25/2023","primary_txt":" Primary completion: 04/28/2027","primary_completion_date":" 04/28/2027","study_txt":" Completion: 04/28/2027","study_completion_date":" 04/28/2027","last_update_posted":"2024-04-24"},{"id":"c81f0280-85de-45ec-aa26-8f5b43ba0005","acronym":"","url":"https://clinicaltrials.gov/study/NCT05734495","created_at":"2023-02-21T16:01:35.955Z","updated_at":"2024-07-02T16:35:10.696Z","phase":"Phase 2","brief_title":"Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia","source_id_and_acronym":"NCT05734495","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BCL2 • MYD88","pipe":" | ","alterations":" MYD88 wild-type","tags":["BCL2 • MYD88"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Jaypirca (pirtobrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 05/02/2023","start_date":" 05/02/2023","primary_txt":" Primary completion: 01/25/2029","primary_completion_date":" 01/25/2029","study_txt":" Completion: 01/25/2033","study_completion_date":" 01/25/2033","last_update_posted":"2024-04-09"},{"id":"32e122d8-81cb-4ac7-b340-b852864b1095","acronym":"","url":"https://clinicaltrials.gov/study/NCT05172700","created_at":"2021-12-29T13:53:40.046Z","updated_at":"2024-07-02T16:35:32.423Z","phase":"","brief_title":"Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer","source_id_and_acronym":"NCT05172700","lead_sponsor":"Loxo Oncology, Inc.","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jaypirca (pirtobrutinib)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2023-10-20"},{"id":"3903b685-96ae-423a-9131-1897503e1953","acronym":"MIRACLE","url":"https://clinicaltrials.gov/study/NCT05677919","created_at":"2023-01-10T14:58:51.145Z","updated_at":"2024-07-02T16:35:32.447Z","phase":"Phase 2","brief_title":"Pirtobrutinib and Venetoclax Combined With Minimal Residual Disease Detection for Previously Untreated Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT05677919 - MIRACLE","lead_sponsor":"Mayo Clinic","biomarkers":" CD20 • CD19 • CCND1 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14) • CD20 expression • CD19 expression","tags":["CD20 • CD19 • CCND1 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CD20 expression • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Jaypirca (pirtobrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 01/31/2023","start_date":" 01/31/2023","primary_txt":" Primary completion: 07/19/2024","primary_completion_date":" 07/19/2024","study_txt":" Completion: 07/19/2025","study_completion_date":" 07/19/2025","last_update_posted":"2023-10-20"}]